By Fineline Cube 
China-based Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotech company focusing on oncology and autoimmune diseases, announced this week that it has made another initial public offering (IPO) filing to the Hong Kong Stock Exchange. Specifics such as the unit price have not yet been disclosed.
Company Overview and Product Pipeline
Founded in 2012, Leads Biolabs has built an innovative product pipeline comprising 12 main assets, six of which are in clinical stages. The company’s portfolio includes LBL-007, an anti-LAG-3 antibody. Previously, in December 2021, Leads Biolabs entered into a licensing agreement with BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235, formerly known as BeiGene) for the global development and manufacturing of LBL-007, with exclusive commercialization rights outside China. The deal was valued at up to USD 772 million. However, in May of this year, the licensing agreement was terminated, and Leads Biolabs regained full global rights to develop, manufacture, and commercialize LBL-007.-Fineline Info & Tech